GlassScriptPhysician profile
Olusegun Apata
NPI 1043298961
$4,492.17
in general payments reported to CMS, 2019-2025
21 companies · $1,276 in 2025
The $1,276 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $210 · 2021: $387 · 2022: $1,222 · 2023: $513 · 2024: $268 · 2025: $1,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318 · Travel and Lodging: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.85 |
| Travel and Lodging | $739.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $899.06 | 2025 | Monarch |
| Ethicon INC. | $584.63 | 2022-2024 | Monarch Platform |
| Glaxosmithkline, LLC. | $519.77 | 2019-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $469.44 | 2019-2025 | Airsupra, Breztri |
| Dompe US, INC. | $389.59 | 2023-2024 | Oxervate |
| Jazz Pharmaceuticals INC. | $381.32 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.02 | 2019-2022 | |
| Harmony Biosciences LLC | $208.28 | 2022 | |
| United Therapeutics Corporation | $157.02 | 2025 | Tyvaso |
| Ani Pharmaceuticals, INC. | $125.00 | 2025 | Purified Cortrophin Gel |
| Eisai INC. | $125.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $97.28 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $94.09 | 2022-2023 | Xarelto |
| Itamar Medical INC | $80.10 | 2022 | |
| Philips North America LLC | $35.34 | 2019-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $27.20 | 2019 | |
| Mylan Specialty L.P. | $20.95 | 2021 | |
| Advanced Respiratory, INC | $20.40 | 2020 | |
| Breas Medical, INC. | $19.20 | 2022 | |
| Mallinckrodt Enterprises LLC | $15.48 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olusegun Apata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.